Development of an Encapsulated Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes
Allogeneic cell therapies often require either immunosuppression or immunoprotection to prevent rejection. To address this issue, ViaCyte is developing a macroencapsulation device that enables delivery, immunoprotection and function of a stem cell-derived therapy without long term immunosuppression. Using current data, this presentation will review our cell manufacturing and immunoprotection device technologies and current efforts to incorporate these into a clinically compliant combination product for the treatment of type 1 diabetes.
Dr. Green attended Cal Poly where he received a B.S. in Biochemistry as well as a B.S. in Microbiology with a minor in Biotechnology. He later earned his M.S. degree at Cal Poly in Biomedical Engineering. In 2004, he received his Ph.D. in Biomedical Engineering from UC Davis with a designated emphasis in Biotechnology. He worked in Dr. Scott Simon’s lab where his dissertation focused on adhesion and signaling events in neutrophil recruitment. Following his Ph.D., he did a post doc at Davis and then at UCSD. He began his career as a Research Scientist at Novocell (now ViaCyte, Inc.) working on the development of a stem-cell derived therapy to treat type 1 diabetes. He later became a Senior Scientist at ViaCyte where he was team leader for a $26M Disease Team award to ViaCyte by the California Institute for Regenerative Medicine (CIRM). He currently serves as Associate Director of Device Engineering and Manufacturing at ViaCyte. He was recently Certified Lean Six Sigma Black Belt and has implemented device manufacturing changes that are projected to save ViaCyte $200,000 annually.
When: Thurs. 12/8/11 4:00 PM
Where: 1005 GBSF